ArticleJTO clinical and research reports2025

Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC.

Sun Min Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.